Evoke Pharma (NASDAQ:EVOK) released its earnings results on Thursday. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02, Fidelity Earnings reports.

EVOK traded up $0.03 on Friday, hitting $0.90. The company had a trading volume of 33,600 shares, compared to its average volume of 554,915. The company’s fifty day moving average price is $0.86 and its 200 day moving average price is $0.81. Evoke Pharma has a 1-year low of $0.50 and a 1-year high of $3.26. The stock has a market cap of $20.70 million, a price-to-earnings ratio of -1.96 and a beta of 1.53.

Several research firms have weighed in on EVOK. Zacks Investment Research cut Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. HC Wainwright reissued a “hold” rating on shares of Evoke Pharma in a research note on Friday, August 9th. Finally, ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Recommended Story: The role of implied volatility with call option volume

Earnings History for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.